Navigation Links
Heart Drug May Be a Cancer Fighter
Date:1/7/2009

Digoxin, used to treat heart failure, slowed cell growth, study says

WEDNESDAY, Jan. 7 (HealthDay News) -- Digoxin, a drug used for many years to treat irregular heart rhythms and heart failure, may also be a cancer-fighting agent, researchers report.

Cancer cells need to create new blood vessels to survive. But many of these cells are oxygen-deprived and need to switch on genes that produce a protein called hypoxia-inducible factor (HIF-1), which help cells survive in low-oxygen conditions.

Digoxin reduces HIF-1, causing cancer cells to die, the scientists from Johns Hopkins University found.

"Anytime you see alternative uses for existing drugs, that always generates a certain amount of excitement," said William Phelps, director of preclinical and translational cancer research at the American Cancer Society. "In the cancer field, we are always looking for any new compounds, so this is an exciting potential."

For the study, Dr. Gregg L. Semenza, director of the vascular program at the Johns Hopkins Institute for Cell Engineering, and his colleagues tested more than 3,000 U.S. Food and Drug Administration-approved drugs for their ability to reduce HIF-1 levels in cancer cells.

They identified 20 drugs that reduced HIF-1 by more than 88 percent; more than half are used to treat heart failure. The researchers then looked specifically at digoxin because it is commonly used and its side effects are well-documented.

The researchers found that prostate cancer cells treated in a laboratory with digoxin grew significantly slower. After three days of treatment, there were fewer cancer cells, and many cells had stopped growing altogether, compared with untreated cells.

"This is really exciting, to find that a drug already deemed safe by the FDA also can inhibit a protein crucial for cancer cell survival," Semenza said in a statement.

To see if digoxin would work on cancer cel
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Drug for cluster headaches may cause heart problems
2. Use of certain lipid measures not more effective in predicting coronary heart disease
3. Restricting Blood Flow May Help Heart Bypass Patients
4. Urban Smog Tough on Young Adults Hearts
5. Stanford study highlights cost-effective method of lowering heart disease risks
6. Vitamin Es lack of heart benefit linked to dosage
7. Drug That Lowers Resting Heart Rate Being Tested
8. Heart Attack Boosts Diabetes Risk
9. Embryonic Stem Cells Repair Human Heart
10. U of M study: Early treatment can reverse heart damage
11. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)... 2,453 women ages 18 to 68 found that lubricant us...ontributed to higher ratings of pleasurable and sa...een recommended to women to improve the comfort of...nal tearing, yet strikingly little available data ...iated vaginal symptoms. , The study, conducted ...
(Date:11/8/2009)...hen Medicare, improve coverage for all Americans ... SUMMARY: Yesterday the United States House of Re...egislation that would strengthen Medicare for seni...that prices millions of Americans out of affordabl...are for America Act (H.R. 3962) makes prescription...
(Date:11/8/2009)...s self-assurance, research finds , , SUN...ve been right when she told you to sit up straight...ke you feel more confident about your thoughts. ,...ht gives a good impression to other people," Richa...professor at Ohio State University, said in a univ...
(Date:11/8/2009)...l Nation,s Job Creators ,, WASHINGTON, Nov. 8 /...e passage of the health care bill (H.R. 3962), Sma...uncil) president & CEO Karen Kerrigan issued t...hose voting for H.R. 3962 voted to burden our nati...axes and penalties. Even in the best of economic t...
(Date:11/8/2009)... "Preventing and Healing AIDS Through Our Inn...t AIDS is a result of multiple, repeated and chron...m stressor agents, which can be either chemical, p... , Oakland, CA (PRWEB) Nov... biologists, physicians, chemists and other scient...
Breaking Medicine News(10 mins):Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:AARP NY Praises House Passage of Health Care Reform Bill 2Health News:AARP NY Praises House Passage of Health Care Reform Bill 3Health News:AARP NY Praises House Passage of Health Care Reform Bill 4Health News:Good Posture May Inspire Confidence 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
...s physicians keep up to date with the latest in Ca...in the detection of cardiovascular disease. CVCTA ...ng to cardiovascular imaging. Led by Medical Direc... 2008 -- CVCTA Education of San Francisco, the l...
...atisfaction with life? Then the pen may be a might... University,s Dr. Steven Toepfer. , Toepfer, an a...at university,s Salem Campus, says that expressive...rican dream. We are wealthier than previous genera...
...TM) Campaign Reaches $1 Million Dollar Donation Go...d Banks in Need , , NEW YORK, Nov. 25 Weight...e donation of one million dollars to two hunger fi...ight Watchers Online Subscribers during Lose For G...
...rtment of Energy,s (DOE) Brookhaven National Labor...B2 for the design of a "medical synchrotron" capab...on to cancerous tumors with minimal damage to surr...lity and benefits of this treatment for cancer pat...
...o-Assisted Thoracic Surgeon Dr. Robert J. Caccaval...nce, Dedication , , SOMERSET, N.J., Nov. 25 ...ay announced that one of its leading thoracic surg...Jersey Monthly,s annual list of "Top Doctors" t...
...ional, Inc. (Amex: BUF ) today announced that it...sthetics for the human market in the United States...ned subsidiary of RxElite Inc.(OTC Bulletin Board:...n overdue accounts owed to MINRAD International, I...
Other Medicine News:Health News:CVCTA Education Expands to Six New Campuses and Finalizes Acquisition Of CVI Training 2Health News:CVCTA Education Expands to Six New Campuses and Finalizes Acquisition Of CVI Training 3Health News:Study: Want to be happier? Be more grateful 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 2Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 3Health News:Weight Watchers Members and Online Subscribers Lose an Estimated 4 Million Pounds in Six Week Period 4Health News:Physicists receive patent for improved cancer therapy device 2Health News:Physicists receive patent for improved cancer therapy device 3Health News:Renowned Thoracic Surgeon Recognized as 'Top Doctor' by Peers in Annual New Jersey Monthly Magazine Survey 2Health News:MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States 2Health News:MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States 3
(Date:11/6/2009)...- Philips Respironics applauds the efforts of the ...o raise awareness about an important public health...elease of the first-ever government study to monit...a milestone in quantifying the size and scope of t...ry leader and sleep therapy manufacturer, Philips ...
(Date:11/6/2009)...-- Cyberonics, Inc. (Nasdaq: CYBX ) today announc...for the second quarter ended October 23, 2009 of i... November 18, 2009 at 5:00 PM EST. The company wi...lts on Thursday, November 19, 2009 at 9:00 AM EST....onference Call Instructions ,, To listen to t...
(Date:11/6/2009)...,, - Trial Will Compare NXL103 With Leading...esistant Staphylococcus Aureus (MRSA) Infections ,...pany focused on the discovery and,development of n...ant global,problem of microbial resistance, announ...l NXL103 (flopristin/linopristin), has started a P...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Skinovative 28R 29 Announces a Safe Non Surgical Liposuction Alternative With the Launch of Zerona 28TM 29 Laser 50923 1Skinovative 28R 29 Announces a Safe Non Surgical Liposuction Alternative With the Launch of Zerona 28TM 29 Laser 50923 2Skinovative 28R 29 Announces a Safe Non Surgical Liposuction Alternative With the Launch of Zerona 28TM 29 Laser 50923 3Tyco to Report Third Quarter Results July 30 2009 50918 1Burrill 26 Company Invests in Taiwan Liposome Company 12918 1Burrill 26 Company Invests in Taiwan Liposome Company 12918 2Burrill 26 Company Invests in Taiwan Liposome Company 12918 3
...ntegrated Biomarker and Imaging Study) Results Dem...rug Development, SAN DIEGO, Calif., Sept. 2 Volc...403], a leading manufacturer of,intravascular ultr...nology,announced today the use of its VH(R) IVUS (...2 trial (Integrated Biomarker and Imaging Study). ...
...ermany, Sept. 2 Data presented today,at the Annua...howed that,the investigational oral Factor Xa inhi...mboembolism (VTE) compared with dalteparin among p...ment surgery. There was a,statistically significan...,observed bleeding rates were low across the group...
Other Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2
Rectangular Square Presentation Case
Essilor Laboratories of America
Abba optical
Distribution Center
Medicine Products: